Expand Box Expand Box Expand Box Close Close

We're standing by & we can help. It's free and confidential.*

Reach us now

Or Call Us Now: (800) 476-6070

*I agree that submitting this form does not create an attorney client relationship and that Weitz & Luxenberg will use the information I am providing to check for conflicts of interest to determine if the firm can assist me.
  • FACEBOOK
  • TWITTER
  • GOOGLE+
  • print

Weitz and Luxenburg logoWeitz and Luxenburg

(800) 476-6070
Paul J. Pennock Managing Attorney, Defective Drugs and Devices

 Get in touchGet in touch

Telephone: (212) 558-5500

Fax: (212) 344-5461

700 Broadway
New York, NY 10003

Summary

Paul J. Pennock is the Chief of the Pharmaceutical and Medical Device litigation department at Weitz & Luxenberg and the firm’s lead litigator in that area.

Litigation Leadership Roles: Mr. Pennock is currently trying the first of what could turn out to be thousands of Fosamax femur fracture cases. Weitz & Luxenberg is taking the lead in a national litigation against Merck, the manufacturer of Fosamax, and Pennock is at the helm. Pennock has been invested in pre-trial preparations, and will now turn his attention to jury selection and Weitz & Luxenberg's evidentiary case. With hundreds of hours already devoted to the case, Pennock said plenty of hard work was still to come. "When my six-year-old says, 'I can't wait until this trial is over,' you know trials are a lot of work," Pennock said.

 

Publications
Speaking engagements
Associations & Licenses
Reach Us Now

Education

  • J.D., St. John's University, 1988
  • B.A., Syracuse University, 1984

Bar Admissions

  • 1989, New York
  • 1992, U.S. District Court Southern District of New York
  • 1997, U.S. District Court, Eastern District of New York
  • 2003, United States Supreme Court
  • 2005, Western District of New York
  • 2011, Northern District of New York

Recent W&L Results in this practice area

  • $2.5 Billion

    W&L helped negotiate one of the largest mass tort settlements in recent history. More than 300 W&L clients are part of the settlement. Claimants had recalled DePuy ASR hips implanted and removed prior to August 31, 2013.

  • $9 Billion

    A Louisiana jury has awarded an extremely large amount to a W&L client who developed bladder cancer after taking Actos. The verdict orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.

Let us help you